Cargando…

Identification of Dihydroorotate Dehydrogenase Inhibitors Using the Cell Painting Assay

Profiling approaches have been increasingly employed for the characterization of disease‐relevant phenotypes or compound perturbation as they provide a broad, unbiased view on impaired cellular states. We report that morphological profiling using the cell painting assay (CPA) can detect modulators o...

Descripción completa

Detalles Bibliográficos
Autores principales: Schölermann, Beate, Bonowski, Jana, Grigalunas, Michael, Burhop, Annina, Xie, Yusheng, Hoock, Joseph G. F., Liu, Jie, Dow, Mark, Nelson, Adam, Nowak, Christine, Pahl, Axel, Sievers, Sonja, Ziegler, Slava
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9828254/
https://www.ncbi.nlm.nih.gov/pubmed/36134475
http://dx.doi.org/10.1002/cbic.202200475
Descripción
Sumario:Profiling approaches have been increasingly employed for the characterization of disease‐relevant phenotypes or compound perturbation as they provide a broad, unbiased view on impaired cellular states. We report that morphological profiling using the cell painting assay (CPA) can detect modulators of de novo pyrimidine biosynthesis and of dihydroorotate dehydrogenase (DHODH) in particular. The CPA can differentiate between impairment of pyrimidine and folate metabolism, which both affect cellular nucleotide pools. The identified morphological signature is shared by inhibitors of DHODH and the functionally tightly coupled complex III of the mitochondrial respiratory chain as well as by UMP synthase, which is downstream of DHODH. The CPA appears to be particularly suited for the detection of DHODH inhibitors at the site of their action in cells. As DHODH is a validated therapeutic target, the CPA will enable unbiased identification of DHODH inhibitors and inhibitors of de novo pyrimidine biosynthesis for biological research and drug discovery.